EZH2 and metabolic dysfunction-associated steatohepatitis: We performed small molecule UNC1999 and EPZ6438 as EZH2 inhibitors and obeticholic acid as clinical trial III compound for NASH treatment in STAM mice to evaluate its efficacy on liver steatosis.